IMMEDIATE-RELEASE PHENYLPROPANOLAMINE STATUS AT FDA QUESTIONED
This article was originally published in The Tan Sheet
Executive Summary
IMMEDIATE-RELEASE PHENYLPROPANOLAMINE STATUS AT FDA QUESTIONED by Caprice-Greystoke in an Aug. 1 citizen petition that responds to a May 20 letter from FDA's OTC Monograph Staff Director William Gilbertson, PharmD, to the Nonprescription Drug Manufacturers Association. Gilbertson informed NDMA that FDA currently considers extended-release phenylpropanolamine to have Category I status for efficacy as an OTC weight-control product but that "existing data are inadequate to support immediate-release doses of 25-50 mg PPA" ("The Tan Sheet" May 30, p. 1).
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning